Company profile: LungLife AI
1.1 - Company Overview
Company description
- Provider of molecular diagnostics for early cancer detection and treatment, offering the LungLB® Test, a blood-based diagnostic that provides additional information to clinicians evaluating indeterminate lung nodules, potentially reducing unnecessary invasive procedures and delays in treatment.
Products and services
- Molecular Diagnostics Services: A molecular-diagnostics service involved in early detection and treatment of cancer, supporting clinicians with additional information when evaluating indeterminate lung nodules to minimize invasive procedures and treatment delays
- Indeterminate Lung Nodule Evaluation Support: A blood-draw-based service that delivers additional information for clinicians assessing indeterminate lung nodules, potentially reducing unnecessary invasive procedures and delays in treatment
- LungLB® Test: A blood-based diagnostic product that delivers additional information for clinicians evaluating indeterminate lung nodules, potentially reducing unnecessary invasive procedures and delays in treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to LungLife AI
NeoGenomics
HQ: United States
Website
- Description: Provider of cancer testing and partnership programs for pathologists and oncologists, offering diagnostic services (flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers), anatomic pathology (histology, tissue staining, digital pathology), NGS panels including Neo Comprehensive™ – Heme Cancers, Early-stage NSCLC Panel, InVisionFirst®-Lung, and pharma services for biomarker discovery, clinical trials, and companion diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoGenomics company profile →
SonoCiné
HQ: United States
Website
- Description: Provider of an imaging solution for breast cancer screening, which the company develops and markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SonoCiné company profile →
Tusk Therapeutics
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapies, discovering and developing unique therapeutic antibodies that harness the immune system to treat cancer, with a growing, diversified pipeline targeting both novel and validated targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tusk Therapeutics company profile →
Heidelberg Pharma
HQ: Germany
Website
- Description: Provider of pre-clinical drug discovery and development services for anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries, including explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology. Also researches, produces, and clinically develops Antibody Amanitin Conjugates (ATACs) using amanitin for cancer therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Heidelberg Pharma company profile →
Trethera
HQ: United States
Website
- Description: Provider of small-molecule therapeutics that control DNA replication and integrity, including TRE-515, an orally bioavailable inhibitor of deoxycytidine kinase (dCK) targeting the nucleotide salvage pathway to treat solid tumors and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trethera company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for LungLife AI
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to LungLife AI
2.2 - Growth funds investing in similar companies to LungLife AI
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for LungLife AI
4.2 - Public trading comparable groups for LungLife AI
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →